We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AVI BioPharma Initiates Clinical Studies for Two RNA-Based Therapeutic Candidates for Treatment of Ebola and Marburg Viruses

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AVI BioPharma Initiates Clinical Studies for Two RNA-Based Therapeutic Candidates for Treatment of Ebola and Marburg Viruses"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AVI BioPharma, Inc. has announced that it initiated dosing in two Phase 1 clinical studies for AVI-6002 and AVI-6003, its lead drug candidates being evaluated for the treatment of Ebola virus and Marburg virus, respectively.

AVI is developing AVI-6002 and AVI-6003 under a competitively awarded contract for up to $291 million from the U.S. Department of Defense through the Joint Project Manager Transformational Medical Technologies (JPM-TMT) program. Both candidates utilize AVI's advanced and proprietary PMOplus™ chemistry.

"These are the first drug candidates employing our PMOplus chemistry to be evaluated in humans, and they are the first AVI programs to enter the clinic based on our prior studies supported by the JPM-TMT program," said Chris Garabedian, president and CEO of AVI BioPharma. "Additionally, we look forward to new and continued opportunities to earn further government support through JPM-TMT."

Each Phase 1 study will be randomized, double-blind, placebo-controlled and involve single escalating doses of AVI-6002 or AVI-6003 to assess the safety, tolerability and pharmacokinetics of each drug candidate in healthy adult volunteers.

In each study, five volunteers will be enrolled in one of six cohorts for a total of up to 30 volunteers. The cohorts will include four volunteers who receive the therapeutic, and one who will receive a placebo.

Preclinical studies of AVI-6002 and AVI-6003 have been a collaborative effort between AVI and scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the U.S. Department of Defense's (DOD) lead medical research laboratory for biological defense. All preclinical studies were conducted at USAMRIID, which has the DOD's only Biosafety Level 4 (BSL4), or maximum containment capability, and is essential for studying the Ebola and Marburg viruses.

Data from preclinical studies published in Nature Medicine demonstrate that AVI-6002 and AVI-6003 provide post-exposure efficacy in non-human primates against Ebola and Marburg viruses, respectively.

In multiple studies evaluating treatment of Ebola virus-infected primates with AVI-6002 and treatment of Marburg-infected primates with AVI-6003, USAMRIID scientists have observed up to 80% survival and 100% survival, respectively, when the viruses were inoculated at 1000 times the lethal dose within the confines of a BSL4 laboratory, compared to control groups where both viruses were universally lethal.